[1] [1] MANDEL I, HAVES ZIV D, GOLDSHTEIN I,et al. BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression[J/OL]. J Immunother Cancer, 2022, 10(9): e004859[2024-11-28]. https://pubmed.ncbi.nlm.nih.gov/36096532/. DOI:10.1136/jitc-2022-004859.

[2] [2] MAO J, FENG Y, ZHU X F,et al. The molecular mechanisms of HLA-G regulatory function on immune cells during early pregnancy[J/OL]. Biomolecules, 2023, 13(8): 1213[2024-11-28]. https://pubmed.ncbi.nlm.nih.gov/37627278/. DOI:10.3390/biom13081213.

[3] [3] LINTAO R C V, RICHARDSON L S, KAMMALA A K,et al. PGRMC2 and HLA-G regulate immune homeostasis in a microphysiological model of human maternal-fetal membrane interface[J/OL]. Commun Biol, 2024, 7(1): 1041[2024-11-28]. https://pubmed.ncbi.nlm.nih.gov/39179795/. DOI:10.1038/s42003-024-06740-2.

[4] [4] SUAREZ-TRUJILLO F, JUAREZ I, VAQUERO-YUSTE C,et al. The immune modulation HLA-G*01: 01: 01 full allele is associated with gastric adenocarcinoma development[J/OL]. Int J Mol Sci,2024, 25(19): 10645[2024-11-28]. https://pubmed.ncbi.nlm.nih.gov/39408976/. DOI:10.3390/ijms251910645.

[5] [5] WANG S Y, WANG J X, XIA Y,et al. Harnessing the potential of HLAG in cancer therapy: advances, challenges, and prospects[J/OL]. J Transl Med, 2024, 22(1): 130[2024-11-28]. https://pubmed.ncbi.nlm.nih.gov/38310272/. DOI:10.1186/s12967-024-04938-w.

[6] [6] LIN A F, YAN W H. HLA-G/ILTs targeted solid cancer immunotherapy: opportunities and challenges[J/OL]. Front Immunol, 2021, 12: 698677[2024-11-28]. https://pubmed.ncbi.nlm.nih.gov/34276691/. DOI:10.3389/fimmu.2021.698677.

[7] [7] WANG J, CHAI Q Y, LEI Z H,et al. LILRB1-HLA-G axis defines a checkpoint driving natural killer cell exhaustion in tuberculosis[J]. EMBO Mol Med, 2024, 16(8): 1755-1790. DOI:10.1038/s44321-024-00106-1.

[8] [8] MARIMPIETRI D, CORRIAS M V, TRIPODI G,et al. Immunomodulatory properties of extracellular vesicles isolated from bone marrow of patients with neuroblastoma: role of PD-L1 and HLA-G[J/OL]. Front Immunol, 2024, 15: 1469771[2024-11-28]. https://pubmed.ncbi.nlm.nih.gov/39512342/. DOI:10.3389/fimmu.2024.1469771.

[10] [10] HAMPTON J T, LIU W R. Diversification of phage-displayed peptide libraries with noncanonical amino acid mutagenesis and chemical modification[J]. Chem Rev, 2024, 124(9): 6051-6077. DOI:10.1021/acs.chemrev.4c00004.

[11] [11] ISTOMINA P V, GORCHAKOV A A, PAOIN C,et al. Phage display for discovery of anticancer antibodies[J]. N Biotechnol,2024, 83: 205-218. DOI:10.1016/j.nbt.2024.08.506.

[12] [12] ZENG D Q, YE Z L, SHEN R F,et al. IOBR: multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures[J/OL]. Front Immunol, 2021, 12: 687975[2024-11-28]. https://pubmed.ncbi.nlm.nih.gov/34276676/. DOI:10.3389/fimmu.2021.687975.

[13] [13] DURMANOVA V, MIKOLASKOVA I, ZSEMLYE E,et al. Association of HLA-G expression, its genetic variants and related neuro-immunomodulation with characteristics of bladder carcinoma[J/OL]. Cancers, 2024, 16(22): 3877[2024-11-28]. https://pubmed.ncbi.nlm.nih.gov/39594832/. DOI:10.3390/cancers16223877.

[14] [14] TRONIK-LE ROUX D, DAOUYA M, PORAS I,et al. HLA-G neoexpression modifies genetic programs governing tumor cell lines[J/OL]. Cancer Immunol Immunother, 2024, 73(12): 247[2024-11-28]. https://pubmed.ncbi.nlm.nih.gov/39358558/. DOI:10.1007/s00262-024-03768-5.

[15] [15] CHEN Q Y, ZHOU W J, ZHANG J G,et al. Prognostic significance of the immune checkpoint HLA-G/ILT-4 in the survival of patients with gastric cancer[J/OL]. Int Immunopharmacol, 2022, 109:108798[2024-11-28]. https://pubmed.ncbi.nlm.nih.gov/35569305/. DOI:10.1016/j.intimp.2022.108798.

[16] [16] LOUSTAU M, ANNA F, DRAN R,et al. HLA-G neo-expression on tumors[J/OL]. Front Immunol, 2020, 11: 1685[2024-11-28]. https://pubmed.ncbi.nlm.nih.gov/32922387/. DOI:10.3389/fimmu.2020.01685.

[17] [17] ATTIA J V D, DESSENS C E, VAN DE WATER R,et al. The molecular and functional characteristics of HLA-G and the interaction with its receptors: where to intervene for cancer immunotherapy?[J/OL]. Int J Mol Sci, 2020, 21(22): 8678[2024-11-28]. https://pubmed.ncbi.nlm.nih.gov/33213057/. DOI:10.3390/ijms21228678.

[18] [18] ANNA F, BOLE-RICHARD E, LEMAOULT J,et al. First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G[J/OL]. J Immunother Cancer, 2021, 9(3): e001998[2024-11-28]. https://pubmed.ncbi.nlm.nih.gov/33737343/. DOI:10.1136/jitc-2020-001998.

[21] [21] GEVA R, VIEITO M, RAMON J,et al. Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors[J/OL]. Cancer Immunol Immunother, 2024, 73(10): 205[2024-11-28]. https://pubmed.ncbi.nlm.nih.gov/39105878/. DOI:10.1007/s00262-024-03790-7.

[22] [22] KONSHINA A G, BOCHAROV E V, KONOVALOVA E V,et al. Structural basis of activity of HER2-targeting construct composed of DARPin G3 and albumin-binding domains[J/OL]. Int J Mol Sci,2024, 25(21): 11370[2024-11-28]. https://pubmed.ncbi.nlm.nih.gov/39518923/. DOI:10.3390/ijms252111370.

[23] [23] XU X S, WANG X X, LI Y,et al. Research progress of ankyrin repeat domain 1 protein: an updated review[J/OL]. Cell Mol Biol Lett, 2024, 29(1): 131[2024-11-28]. https://pubmed.ncbi.nlm.nih.gov/39420247/. DOI:10.1186/s11658-024-00647-w.

[24] [24] MORSELLI M, HOLTON T R, PELLEGRINI M,et al. Design and construction of a designed ankyrin repeat protein (DARPin) display library[J/OL]. Curr Protoc, 2024, 4(1): e960[2024-11-28]. https://pubmed.ncbi.nlm.nih.gov/38206591/. DOI:10.1002/cpz1.960.

[25] [25] SCHNIDER S T, ALESSANDRA VIGANO M, AFFOLTER M,et al. Functionalized protein binders in developmental biology[J]. Annu Rev Cell Dev Biol, 2024, 40(1): 119-142. DOI:10.1146/annurev-cellbio-112122-025214.

[26] [26] GABRIELE F, PALERMA M, IPPOLITI R,et al. Recent advances on affibody- and DARPin-conjugated nanomaterials in cancer therapy[J/OL]. Int J Mol Sci, 2023, 24(10): 8680[2024-11-28]. https://pubmed.ncbi.nlm.nih.gov/37240041/. DOI:10.3390/ijms24108680.

[27] [27] SALTARELLA I, LINK A, LAMANUZZI A,et al. Improvement of daratumumab- or elotuzumab-mediated NK cell activity by the bispecific 4-1BB agonist, DARPin -FAPx4-1BB: a preclinical study in multiple myeloma[J/OL]. Biomed Pharmacother, 2024, 176:116877[2024-11-28]. https://pubmed.ncbi.nlm.nih.gov/38850654/. DOI:10.1016/j.biopha.2024.116877.

[28] [28] RIGAMONTI N, VEITONMKI N, DOMKE C,et al. A multispecific anti-CD40 DARPin construct induces tumor-selective CD40 activation and tumor regression[J]. Cancer Immunol Res, 2022, 10(5): 626-640. DOI:10.1158/2326-6066.CIR-21-0553.

[29] [29] BIANCHI M, REICHEN C, CROSET A,et al. The CD33xCD123 xCD70 multispecific CD3-engaging DARPin MP0533 induces selective T cell-mediated killing of AML leukemic stem cells[J]. Cancer Immunol Res, 2024, 12(7): 921-943. DOI:10.1158/2326-6066.CIR-23-0692.